SCHEMBL257527

SCHEMBL257527

COCc1c(C)cccc1C(=O)Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
USP2 O75604 1/20 0.48
TP53 P04637 1/20 0.48
GAA P10253 1/20 0.48
LMNA P02545 4/20 0.44
PPARG P37231 2/20 0.43
PPARA Q07869 2/20 0.43
HPGD P15428 2/20 0.41
SLC22A12 Q96S37 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
RECQL P46063 1/20 0.40
FFAR1 O14842 1/20 0.40
ERCC5 P28715 1/20 0.40
FEN1 P39748 1/20 0.40
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15197234 0.83 SMN1; SMN2 (0.48) SMN1; SMN2USP2TP53GAALMNA
SCHEMBL16280257 0.81 ALDH1A1 (0.52) LMNAPPARGPPARAHPGDSLC22A12
SCHEMBL1515738 0.79 SMN1; SMN2 (0.60) SMN1; SMN2USP2TP53GAALMNA
SCHEMBL30394799 0.79 SMN1; SMN2 (0.60) SMN1; SMN2USP2TP53GAALMNA
SCHEMBL3468225 0.78 SMN1; SMN2 (0.51) SMN1; SMN2USP2TP53GAALMNA
SCHEMBL257528 0.75 SMN1; SMN2 (0.49) SMN1; SMN2USP2TP53GAALMNA
SCHEMBL3278890 0.75 SMN1; SMN2 (0.49) SMN1; SMN2USP2TP53GAALMNA
SCHEMBL257537 0.73 NPC1 (0.42) SMN1; SMN2GAAKMT2AMAPTALDH1A1
SCHEMBL7129795 0.73 MEN1 (0.62) USP2TP53LMNAKMT2AMEN1
SCHEMBL29861033 0.71 NPC1 (0.63) SMN1; SMN2USP2TP53GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 SMN1; SMN2 2704/4885USP2 4464/4885TP53 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.